Compare Albertsons Companies Inc (ACI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs Mesoblast Limited — how do they compare? Albertsons Companies Inc trades at $12.29 (market cap $5.95B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Albertsons Companies Inc is far larger — about 2.7× Mesoblast Limited's market cap, and Albertsons Companies Inc pays a 5.55% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| ACI | MESO | |
|---|---|---|
Market Cap | $5.95B | $2.21B |
Sector | Consumer Staples | Technology |
52-Week High | $19.74 | $20.96 |
52-Week Low | $11.03 | $12.88 |
Enterprise Value | $21.35B | $2.21B |
Dividend Yield | 5.55% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
